Aldose reductase modulates cardiac glycogen synthase kinase-3β phosphorylation during ischemia-reperfusion

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 303, Issue 3, 2012, Pages 297-308

  Abdillahi, Mariane ^a,b   Ananthakrishnan, Radha ^a   Vedantham, Srinivasan ^a   Shang, Linshan ^b   Zhu, Zhengbin ^b   Rosario, Rosa ^a   Zirpoli, Hylde ^b   Bohren, Kurt M ^c   Gabbay, Kenneth H ^c   Ramasamy, Ravichandran ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b Department of Medicine   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Aldose reductase; Cardioprotection; Glycogen synthase kinase 3 ; Ischemia reperfusion

Indexed keywords

ALDEHYDE REDUCTASE; GLYCOGEN SYNTHASE KINASE 3BETA; LACTATE DEHYDROGENASE; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B INHIBITOR; PROTEIN KINASE C ALPHA INHIBITOR; PROTEIN KINASE C BETA INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; ENZYME RELEASE; HEART LEFT VENTRICLE PRESSURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REPERFUSION INJURY;

ALDEHYDE REDUCTASE; ANIMALS; APOPTOSIS; CELL LINE; DISEASE MODELS, ANIMAL; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MYOCARDIAL REPERFUSION INJURY; MYOCYTES, CARDIAC; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHORYLATION; PROTEIN KINASE C; PROTEIN KINASE C-ALPHA; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; RECOVERY OF FUNCTION; RNA INTERFERENCE; TRANSFECTION; VENTRICULAR FUNCTION, LEFT; VENTRICULAR PRESSURE;

EID: 84864532961     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00999.2011     Document Type: Article

References (45)

1. Ananthakrishnan R, Kaneko M, Hwang YC, Quadri N, Gomez T, Li Q, Caspersen C, Ramasamy R. Aldose reductase mediates myocardial ischemia-reperfusion injury in part by opening mitochondrial permeability transition pore. Am J Physiol Heart Circ Physiol 296: H333-H341, 2009.
2. Braunwald E, Kloner RA. Myocardial reperfusion: a double-edged sword? J Clin Invest 76: 1713-1719, 1985.
3. Cheng H, Woodgett J, Maamari M, Force T. Targeting GSK-3 family members in the heart: a very sharp double-edged sword. J Mol Cell Cardiol 51: 607-613, 2011.
4. Connern CP, Halestrap AP. Purification and N-terminal sequencing of peptidyl-prolyl cis-trans-isomerase from rat liver mitochondrial matrix reveals the existence of a distinct mitochondrial cyclophilin. Biochem J 284: 381-385, 1992.
5. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378: 785-789, 1995.
6. Dorn GW. Mechanisms of non-apoptotic programmed cell death in diabetes and heart failure. Cell Cycle 9: 3442-3448, 2010.
7. Fujio Y, Nguyen T, Wencker D, Kitsis RN, Walsh K. Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reper-fusion injury in mouse heart. Circulation 101: 660-667, 2000.
8. Gabbay KH, Bohren KM, Morello R, Bertin T, Liu J, Vogel P. Ascorbate synthesis pathway: dual role of ascorbate in bone homeostasis. J Biol Chem 285: 19510-19520, 2010.
9. Geraldes P, King GL. Activation of protein kinase C isoforms and its impact on diabetic complications. Circ Res 106: 1319-1331, 2010.
10. Gomez L, Paillard M, Thibault H, Derumeaux G, Ovize M. Inhibition of GSK3beta by postconditioning is required to prevent opening of the mitochondrial permeability transition pore during reperfusion. Circulation 117: 2761-2768, 2008.
11. Grimshaw CE, Bohren KM, Lai CJ, Gabbay KH. Human aldose reductase: rate constants for a mechanism including interconversion of ternary complexes by recombinant wild-type enzyme. Biochemistry 34: 14356-14365, 1995.
12. Gross ER, Hsu AK, Gross GJ. GSK3beta inhibition and K(ATP) channel opening mediate acute opioid-induced cardioprotection at reperfusion. Basic Res Cardiol 102: 341-349, 2007.
13. Halestrap AP. Mitochondria and reperfusion injury of the heart-a holey death but not beyond salvation. J Bioenerg Biomembr 41: 113-121, 2009.
14. Halestrap AP, Pasdois P. The role of the mitochondrial permeability transition pore in heart disease. Biochim Biophys Acta 1787: 1402-1415, 2009.
15. Hasselbaink DM, Glatz JF, Luiken JJ, Roemen TH, Van der Vusse GJ. Ketone bodies disturb fatty acid handling in isolated cardiomyocytes derived from control and diabetic rats. Biochem J 371: 753-760, 2003.
16. Hwang YC, Kaneko M, Bakr S, Liao H, Lu Y, Lewis ER, Yan S, Ii S, Itakura M, Rui L, Skopicki H, Homma S, Schmidt AM, Oates PJ, Szabolcs M, Ramasamy R. Central role for aldose reductase pathway in myocardial ischemic injury. FASEB J 18: 1192-1199, 2004.
17. Hwang YC, Sato S, Tsai JY, Yan S, Bakr S, Zhang H, Oates PJ, Ramasamy R. Aldose reductase activation is a key component of myo-cardial response to ischemia. FASEB J 16: 243-245, 2002.
18. Hwang YC, Shaw S, Kaneko M, Redd H, Marrero MB, Ramasamy R. Aldose reductase pathway mediates JAK-STAT signaling: a novel axis in myocardial ischemic injury. FASEB J 19: 795-797, 2005.
19. Iwata K, Matsuno K, Nishinaka T, Persson C, Yabe-Nishimura C. Aldose reductase inhibitors improve myocardial reperfusion injury in mice by a dual mechanism. J Pharmacol Sci 102: 37-46, 2006.
20. Javadov SA, Lim KH, Kerr PM, Suleiman MS, Angelini GD, Hal-estrap AP. Protection of hearts from reperfusion injury by propofol is associated with inhibition of the mitochondrial permeability transition. Cardiovasc Res 45: 360-369, 2000.
21. Jez JM, Penning TM. The aldo-keto reductase (AKR) superfamily: an update. Chem Biol Interact 130-132: 499-525, 2001.
22. Juhaszova M, Zorov DB, Kim SH, Pepe S, Fu Q, Fishbein KW, Ziman BD, Wang S, Ytrehus K, Antos CL, Olson EN, Sollott SJ. Glycogen synthase kinase-3beta mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J Clin Invest 113: 1535-1549, 2004.
23. Juhaszova M, Zorov DB, Yaniv Y, Nuss HB, Wang S, Sollott SJ. Role of glycogen synthase kinase-3beta in cardioprotection. Circ Res 104: 1240-1252, 2009.
24. Kerr PM, Suleiman MS, Halestrap AP. Reversal of permeability transition during recovery of hearts from ischemia and its enhancement by pyruvate. Am J Physiol Heart Circ Physiol 276: H496-H502, 1999.
25. Kong L, Andrassy M, Chang JS, Huang C, Asai T, Szabolcs MJ, Homma S, Liu R, Zou YS, Leitges M, Yan SD, Ramasamy R, Schmidt AM, Yan SF. PKCbeta modulates ischemia-reperfusion injury in the heart. Am J Physiol Heart Circ Physiol 294: H1862-H1870, 2008.
26. Markou T, Cullingford TE, Giraldo A, Weiss SC, Alsafi A, Fuller SJ, Clerk A, Sugden PH. Glycogen synthase kinases 3alpha and 3beta in cardiac myocytes: regulation and consequences of their inhibition. Cell Signal 20: 206-218, 2008.
27. Murphy E. Inhibit GSK-3beta or there's heartbreak dead ahead. J Clin Invest 113: 1526-1528, 2004.
28. Murphy E, Steenbergen C. Does inhibition of glycogen synthase kinase protect in mice? Circ Res 103: 226-228, 2008.
29. Murphy E, Steenbergen C. Inhibition of GSK-3beta as a target for cardioprotection: the importance of timing, location, duration and degree of inhibition. Expert Opin Ther Targets 9: 447-456, 2005.
30. Naruse K, Rask-Madsen C, Takahara N, Ha SW, Suzuma K, Way KJ, Jacobs JR, Clermont AC, Ueki K, Ohshiro Y, Zhang J, Goldfine AB, King GL. Activation of vascular protein kinase C-beta inhibits Akt-dependent endothelial nitric oxide synthase function in obesity-associated insulin resistance. Diabetes 55: 691-698, 2006.
31. Nishino Y, Webb IG, Davidson SM, Ahmed AI, Clark JE, Jacquet S, Shah AM, Miura T, Yellon DM, Avkiran M, Marber MS. Glycogen synthase kinase-3 inactivation is not required for ischemic preconditioning or postconditioning in the mouse. Circ Res 103: 307-314, 2008.
32. Pap M, Cooper GM. Role of glycogen synthase kinase-3 in the phos-phatidylinositol 3-Kinase/Akt cell survival pathway. J Biol Chem 273: 19929-19932, 1998.
33. Ramana KV, Friedrich B, Tammali R, West MB, Bhatnagar A, Srivastava SK. Requirement of aldose reductase for the hyperglycemic activation of protein kinase C and formation of diacylglycerol in vascular smooth muscle cells. Diabetes 54: 818-829, 2005.
34. Ramasamy R, Goldberg IJ. Aldose reductase and cardiovascular diseases, creating human-like diabetic complications in an experimental model. Circ Res 106: 1449-1458, 2010.
35. Ramasamy R, Oates PJ, Schaefer S. Aldose reductase inhibition protects diabetic and nondiabetic rat hearts from ischemic injury. Diabetes 46: 292-300, 1997.
36. Ramasamy R, Trueblood N, Schaefer S. Metabolic effects of aldose reductase inhibition during low-flow ischemia and reperfusion. Am J Physiol Heart Circ Physiol 275: H195-H203, 1998.
37. Shang L, Ananthakrishnan R, Li Q, Quadri N, Abdillahi M, Zhu Z, Qu W, Rosario R, Toure F, Yan SF, Schmidt AM, Ramasamy R. RAGE modulates hypoxia/reoxygenation injury in adult murine cardio-myocytes via JNK and GSK-3beta signaling pathways. PLoS One 5: e10092, 2010.
38. Shaw S, Wang X, Redd H, Alexander GD, Isales CM, Marrero MB. High glucose augments the angiotensin II-induced activation of JAK2 in vascular smooth muscle cells via the polyol pathway. J Biol Chem 278: 30634-30641, 2003.
39. Tong H, Imahashi K, Steenbergen C, Murphy E. Phosphorylation of glycogen synthase kinase-3beta during preconditioning through a phos-phatidylinositol-3-kinase-dependent pathway is cardioprotective. Circ Res 90: 377-379, 2002.
40. Tracey WR, Magee WP, Ellery CA, MacAndrew JT, Smith AH, Knight DR, Oates PJ. Aldose reductase inhibition alone or combined with an adenosine A(3) agonist reduces ischemic myocardial injury. Am J Physiol Heart Circ Physiol 279: H1447-H1452, 2000.
41. Wetzelberger K, Baba SP, Thirunavukkarasu M, Ho YS, Maulik N, Barski OA, Conklin DJ, Bhatnagar A. Postischemic deactivation of cardiac aldose reductase: role of glutathione S-transferase P and glutare-doxin in regeneration of reduced thiols from sulfenic acids. J Biol Chem 285: 26135-26148, 2010.
42. White SM, Constantin PE, Claycomb WC. Cardiac physiology at the cellular level: use of cultured HL-1 cardiomyocytes for studies of cardiac muscle cell structure and function. Am J Physiol Heart Circ Physiol 286: H823-H829, 2004.
43. Yamaoka T, Nishimura C, Yamashita K, Itakura M, Yamada T, Fujimoto J, Kokai Y. Acute onset of diabetic pathological changes in transgenic mice with human aldose reductase cDNA. Diabetologia 38: 255-261, 1995.
44. Yan L, Huang H, Tang QZ, Zhu LH, Wang L, Liu C, Bian ZY, Li H. Breviscapine protects against cardiac hypertrophy through blocking PKC-alpha-dependent signaling. J Cell Biochem 109: 1158-1171, 2010.
45. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med 357: 1121-1135, 2007.